Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH
(WorldNews Netherlands)

FOR IMMEDIATE RELEASE Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Additional preclinical data presented on BCMA-targeting NK cell engager AFM26 Heidelberg, Germany, December 11, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the presentation of clinical and preclinical data on its tetravalent, bispecific natural killer (NK) cell engagers at the 59th American...